Trials / Completed
CompletedNCT01309646
Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine
Immunogenicity and Safety of GlaxoSmithKline Biologicals' DTPa-IPV/Hib (Infanrix™-IPV+Hib) Vaccine in Healthy Korean Infants
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 454 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 42 Days – 69 Days
- Healthy volunteers
- Accepted
Summary
This study is designed to evaluate the safety and immunogenicity of Infanrix™-IPV+Hib vaccine when administered as a primary vaccination course to healthy Korean infants at 2, 4 and 6 months of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Infanrix™-IPV+Hib | Intramuscular, 3 doses |
| BIOLOGICAL | Infanrix™ IPV | Intramuscular, 3 doses |
| BIOLOGICAL | Hiberix™ | Intramuscular, 3 doses |
| BIOLOGICAL | Synflorix™ | Intramuscular, 3 doses |
| BIOLOGICAL | Rotarix™ | Oral, 2 doses |
Timeline
- Start date
- 2011-03-04
- Primary completion
- 2012-02-24
- Completion
- 2012-02-24
- First posted
- 2011-03-07
- Last updated
- 2019-11-27
- Results posted
- 2013-04-02
Locations
11 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01309646. Inclusion in this directory is not an endorsement.